CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 30, 2019-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2019, on Thursday, May 9, 2019, before the opening of the financial markets.

Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, May 9, 2019 to discuss its first quarter financial results. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 4271217. The call will also be webcast LIVE and can be accessed via the Investors section of the Company’s website at http://ir.akebia.com.

A replay of the conference call will be available two hours after the completion of the call through May 15, 2019. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number 4271217. An online archive of the conference call can be accessed via the Investors section of the Company’s website at http://ir.akebia.com.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190430005194/en/

Source: Akebia Therapeutics, Inc.

Investor Contact
Kristen K. Sheppard, Esq
ir@akebia.com